| Entry |
|
|---|
| Name |
Caffeine citrate (USP);
Cafcit (TN) |
|---|
| Product |
|
|---|
| Generic |
CAFFEINE CITRATE (American Regent), CAFFEINE CITRATE (Armas Pharmaceuticals), CAFFEINE CITRATE (AuroMedics Pharma LLC), CAFFEINE CITRATE (Exela Pharma Sciences), CAFFEINE CITRATE (Exela Pharma Sciences), CAFFEINE CITRATE (Exela Pharma Sciences), CAFFEINE CITRATE (Exela Pharma Sciences), CAFFEINE CITRATE (Fresenius Kabi USA), CAFFEINE CITRATE (Fresenius Kabi USA), CAFFEINE CITRATE (Fresenius Kabi USA), CAFFEINE CITRATE (Micro Labs Limited), CAFFEINE CITRATE (Micro Labs Limited), CAFFEINE CITRATE (Sagent Pharmaceuticals), CAFFEINE CITRATE (Sun Pharmaceutical Industries), CAFFEINE CITRATE (Sun Pharmaceutical Industries), CAFFEINE CITRATE ORAL SOLUTION (Armas Pharmaceuticals) |
|---|
| Formula |
C8H10N4O2. C6H8O7
|
|---|
| Exact mass |
386.1074
|
|---|
| Mol weight |
386.3141
|
|---|
| Structure |
|
|---|
| Class |
Respiratory system agent
DG01616 Xanthine derivative
DG01612 Xanthine-type central nervous system stimulant
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG02855 CYP2E1 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Product (DG00974): | D00528<JP> D01453<JP> D07603<US> |
|
|---|
| Efficacy |
Stimulant (central), Analeptic, Adenosine receptor antagonist, Phosphodiesterase inhibitor |
|---|
| Comment |
Xanthine derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04270 | Vascular smooth muscle contraction |
|
|---|
| Metabolism |
Enzyme: CYP1A2 [HSA: 1544]; CYP3A4 [HSA: 1576], CYP2E1 [HSA: 1571]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
D DERMATOLOGICALS
D11 OTHER DERMATOLOGICAL PREPARATIONS
D11A OTHER DERMATOLOGICAL PREPARATIONS
D11AX Other dermatologicals
D11AX26 Caffeine
D07603 Caffeine citrate (USP) <US>
N NERVOUS SYSTEM
N06 PSYCHOANALEPTICS
N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06BC Xanthine derivatives
N06BC01 Caffeine
D07603 Caffeine citrate (USP) <US>
Classification of Japanese OTC drugs [BR:br08313]
Agents for nervous and sensory systems
05 Alertness drug
D07603 Caffeine citrate (USP)
Risk category of Japanese OTC drugs [BR:br08312]
Third-class OTC drugs
Inorganic and organic chemicals
Anhydrous caffeine
D07603 Caffeine citrate (USP)
Drug groups [BR:br08330]
Respiratory system agent
DG01616 Xanthine derivative
DG01612 Xanthine-type central nervous system stimulant
DG00974 Caffeine
D07603 Caffeine citrate
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG00974 Caffeine
D07603 Caffeine citrate
DG02855 CYP2E1 substrate
DG00974 Caffeine
D07603 Caffeine citrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00974 Caffeine
D07603 Caffeine citrate
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adenosine
ADORA1
D07603 Caffeine citrate (USP) <US>
ADORA2A
D07603 Caffeine citrate (USP) <US>
Enzymes
Hydrolases (EC3)
Phosphodiesterases
PDE
D07603 Caffeine citrate (USP) <US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D07603
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D07603
Drug groups [BR:br08330]
Respiratory system agent
DG01616 Xanthine derivative
DG01612 Xanthine-type central nervous system stimulant
DG00974 Caffeine
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG00974 Caffeine
DG02855 CYP2E1 substrate
DG00974 Caffeine
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00974 Caffeine
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 27
1 C8y C 16.7313 -7.4914
2 C8y C 16.7313 -8.9615
3 C8y C 17.9214 -6.7913
4 N4y N 15.4712 -7.0713
5 N4y N 17.9214 -9.5915
6 N5x N 15.4712 -9.3815
7 N4y N 19.1815 -7.5614
8 O5x O 17.9214 -5.4612
9 C8x C 14.6311 -8.2614
10 C1a C 14.9811 -5.7412
11 C8y C 19.1815 -8.8915
12 C1a C 17.9214 -11.0617
13 C1a C 20.3716 -6.8613
14 O5x O 20.4416 -9.5915
15 C1d C 27.5800 -7.6300
16 C1b C 26.3900 -8.3300
17 C1b C 28.7700 -8.3300
18 C6a C 28.2800 -6.4400
19 O1a O 26.8800 -6.4400
20 C6a C 25.2000 -7.7000
21 C6a C 28.7700 -9.7300
22 O6a O 27.5800 -5.2500
23 O6a O 29.6800 -6.4400
24 O6a O 23.9400 -8.4000
25 O6a O 25.2000 -6.3000
26 O6a O 30.0300 -10.4300
27 O6a O 27.5800 -10.4300
BOND 27
1 1 2 2
2 1 3 1
3 1 4 1
4 2 5 1
5 2 6 1
6 3 7 1
7 3 8 2
8 4 9 1
9 4 10 1
10 5 11 1
11 5 12 1
12 7 13 1
13 11 14 2
14 6 9 2
15 7 11 1
16 15 16 1
17 15 17 1
18 15 18 1
19 15 19 1
20 16 20 1
21 17 21 1
22 18 22 1
23 18 23 2
24 20 24 1
25 20 25 2
26 21 26 1
27 21 27 2
|
|---|
